Why the Cheapest Generic Manufacturer Usually Loses The dominant assumption inside generic pharma for the past three decades has been […]

1. Why This Analysis Exists: The $234 Billion Question Nobody Is Answering Precisely Between 2025 and 2034, 118 biologic medicines

I. Executive Summary and Scope The $1.6 trillion global pharmaceutical industry runs on a single underlying premise: time-limited exclusivity justifies

Executive Summary Generic drugs now account for roughly 90% of all U.S. prescriptions filled, yet constitute less than 13% of

A deep-dive for pharma/biotech IP strategists, pipeline analysts, and buy-side investors. Part I: The Japanese Pharmaceutical Market Sizing Up the

The pharmacy counter is one of the most consequential decision points in American healthcare. A prescription that a physician deemed

Who this is for: Pharma and biotech IP teams, portfolio managers, R&D leads, M&A counsel, and institutional investors with exposure

Section I: The Economic Architecture of Pharmaceutical Patents The 20-Year Fiction: Why Statutory Term and Commercial Life Are Two Different

Who this is for: Pharma and biotech IP counsel, portfolio managers, R&D leads, generic drug strategy teams, business development executives,